№ lp_2_1_12774
File format: docx
Character count: 26100
File size: 85 KB
Version:
3.1
Date:
January 2026
Location/Service/Organisation:
[location/service/organisation]
PGD Development Group:
Reproductive Health PGDs Short Life Working Group
Reviewed by:
College of Sexual and Reproductive Health (CoSRH)
Date Template Comes into Effect:
1st April 2026
Review Date:
1st September 2028
Expiry Date:
31st March 2029
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Authors:
Aaron McConville; James Davis
Affiliation:
School of Engineering, Ulster University, Jordanstown, Northern Ireland, BT37 0QB
Institution:
Ulster University
Document Type:
Scientific research article
Field:
Electrochemical sensing; Biomedical engineering; Materials science
Keywords:
palladium; composite; microneedle; transdermal; sensing array
Total Words:
3107
Text Words:
2954
Figures:
3
References:
47
Materials Investigated:
Palladium powder; Polystyrene; Polycarbonate; L-cysteine; Potassium ferrocyanide; Calcium alginate
Methodology:
Solvent casting of metal particle–polymer mixtures into silicone microneedle moulds
Application Area:
Transdermal electroanalysis
Experimental Model:
Calcium alginate hydrogel skin mimic with ferrocyanide redox probe and Parafilm™ barrier
Array Configuration:
10 × 10 pyramidal microneedles (200 × 200 × 350 µm)
Year:
2019
Region / City:
Australia
Topic:
Hormone Replacement Therapy (HRT)
Document Type:
Regulatory Submission
Organization / Institution:
Besins Healthcare Australia Pty Ltd
Author:
Not specified
Target Audience:
Health professionals and regulatory authorities
Period of Effectiveness:
Not specified
Approval Date:
8 May 2019
Modification Date:
Not specified
Registration Status:
TGA Registered
Indications:
Estrogen deficiency, prevention of osteoporosis, menstrual irregularities, hormone replacement therapy
Purpose:
Request for listing of medications in General Schedule
Product Names:
Estrogel®, Prometrium®, Estrogel Pro
Safety Data:
Includes safety outcomes such as breast pain, tenderness, breakthrough bleeding, and breast cancer risk
Comparator Products:
Sandrena®, MPA (medroxyprogesterone acetate)
Clinical Claims:
Efficacy and safety comparison of Estrogel and MP to Sandrena and MPA
Source:
Tables 1.2, pp23-24
Year:
2023
Region / city:
USA, UK, Canada, Switzerland, Italy
Topic:
Endocrinology, Biomineralisation, Bone Health
Document Type:
Review Article
Institution:
University of Connecticut, University of Southampton, Memorial University of Newfoundland, Massachusetts General Hospital, Geneva University Hospitals, University of Florence, Mayo Clinic, University of Oxford
Author:
Andrew Arnold, Elaine Dennison, Christopher S. Kovacs, Michael Mannstadt, René Rizzoli, Maria Luisa Brandi, Bart Clarke, Rajesh V. Thakker
Target Audience:
Researchers, Medical Professionals, Endocrinologists
Period of Activity:
Not specified
Date of Approval:
Not specified
Date of Changes:
Not specified
Contextual Description:
Review article on the hormonal regulation of biomineralisation, focusing on physiological and pathological processes, and their impact on skeletal health and mineral metabolism.
Year:
2010
Region / City:
Boston, MA
Theme:
Reproductive Health
Document Type:
Protocol
Institution:
Harvard Medical School
Author:
Unknown
Target Audience:
Female participants in NHS II aged 25-42 in 1989
Period of Action:
Not specified
Approval Date:
February 26, 2010
Modification Date:
Not specified
Note:
Year
Theme:
Emergency Hormonal Contraception
Document Type:
Standard Operating Procedure (SOP)
Organization / Institution:
Pharmacy
Target Audience:
Pharmacists, Healthcare Professionals
Guidance:
The Pharmacy First Service for Emergency Hormonal Contraception (EHC)
Purpose:
To describe the process for implementing the Pharmacy First Service for Emergency Hormonal Contraception
Scope:
Provision of Emergency Hormonal Contraception to patients aged 13 and over by registered pharmacists
Document Type:
Educational text
Subject:
Female reproductive system anatomy and physiology
Scope:
Structure and function of reproductive organs
Primary Organs:
Ovaries
Secondary Organs:
Fallopian tubes, uterus, vagina, mammary glands, external genitalia
Physiological Processes:
Ovulation, fertilization, menstruation, ovarian cycle, uterine cycle, menopause
Hormones Mentioned:
Follicle-stimulating hormone, luteinizing hormone, estrogen, progesterone, prolactin, oxytocin, gonadotropin-releasing hormone
Anatomical Structures:
Ovarian follicles, corpus luteum, endometrium, cervix, infundibulum, fimbriae, placenta
Biological Focus:
Gamete production, hormonal regulation, fetal development, lactation
Target Audience:
Students of human biology or anatomy
Language:
English
Year:
2023
Region / City:
Lancashire
Theme:
Emergency Hormonal Contraception, Sexual Health
Document Type:
Service Specification
Organization:
Lancashire County Council
Author:
Marie Demaine
Target Audience:
Community Pharmacists, Health Care Professionals, Service Users
Period of Validity:
1st April 2023 – 31st March 2024
Approval Date:
2023-03-31
Modification Date:
N/A
Note:
Year
Document Type:
Medical claim form
Organization:
PHARMACY FIRST
Target Audience:
Pharmacists
Patient Age Groups:
13, 14, 15, 16 or >16
Medications Provided:
UPA-EC, LNG-EC, Desogestrel x 3 months bridging POP
Referral Sources:
GP, OOH, GUM, SH Clinic, Gateway
Consultation Outcomes:
EHC, POP
Consultation Fees:
£25, £15
Year:
2021
Region / City:
Bilbrook
Topic:
Contraception
Document Type:
Patient Information Leaflet
Organization / Institution:
Bilbrook Medical Centre
Author:
Bilbrook Medical Centre
Target Audience:
Patients using Sayana® Press
Duration:
13 weeks
Approval Date:
May 2021
Review Date:
May 2023
Changes Date:
N/A
Year:
N/A
Region / City:
Sub-Saharan Africa
Subject:
Health workers, contraceptives, knowledge, attitudes, practices
Document Type:
Search strategy
Organization / Institution:
N/A
Author:
N/A
Target Audience:
Researchers, healthcare professionals
Period of Validity:
N/A
Date of Approval:
N/A
Date of Changes:
N/A
Year:
2013
Region / City:
Cocke County, Sevier County, East Tennessee
Topic:
Substance Use and Abuse
Document Type:
Report
Organization:
Tennessee Department of Health
Author:
Erica Wilson, M.P.H.
Target Audience:
Female inmates, health professionals, community partners
Period of Implementation:
January 30, 2014 - September 2014
Approval Date:
January 30, 2014
Modification Date:
February 7, 2014
Program:
Voluntary Reversible Long Acting Contraceptive (VRLAC) Jail Initiative
Outreach Partners:
UT Medical Center Family Medical Residency Program
Number of Participants:
142 women
Project Contact:
Erica Wilson, M.P.H.
Contact Information:
4310 Papermill Rd. Knoxville, TN 37909-2018, 865-909-9404 Ext. 103, [email protected]
Context:
A public health report describing a pilot project aimed at educating female inmates in East Tennessee jails about NAS and offering voluntary reversible long-acting contraceptives (VRLAC) to prevent NAS births.
Note:
Year
Topic:
Oral contraception, Health review
Document type:
Medical form
Organization / institution:
South View Partnership
Target audience:
Patients requesting repeat oral contraceptive prescriptions
Period of validity:
Annual
Year:
2012
Region / City:
Nairobi, Kenya
Subject:
Reproductive Health, Contraceptive Training
Document Type:
Official Letter
Organization:
Ministry of Public Health and Sanitation, Tupange – Kenya Urban Reproductive Health Initiative
Author:
Nelson Keyonzo
Target Audience:
Health service providers
Training Dates:
23–27 April 2012, 30 April–4 May 2012
Contact:
Emmah Kariuki, Tel. 0721 759646
Partners:
Jhpiego, Johns Hopkins University Center for Communication Programs, Marie Stopes International, NCAPD, Pharm Access Africa
Year:
2026
Region / City:
Global
Topic:
Reproductive Health
Document Type:
Informational Guide
Institution / Organization:
Not specified
Author:
Not specified
Target Audience:
Individuals seeking knowledge on fertility and contraception
Methods Covered:
Natural Family Planning, Cervical Mucus Method, Condoms, Diaphragm, Mini-pill, Injection, Implant, Intrauterine System, Intrauterine Device
Usage Instructions:
Detailed for each method
Benefits and Risks:
Provided for each method
Year:
2025
Region / Location:
[location/service/organisation]
Document Type:
Patient Group Direction (PGD)
Issuing Organization:
College of Sexual and Reproductive Healthcare (CoSRH)
Authors / Contributors:
Alison Crompton, Bola Sotubo, Carmel Lloyd, Dr Cindy Farmer, Clare Livingstone, Dipti Patel, Emma Anderson, Heather Randle, Julia Hogan, Kate Devonport, Kirsty Armstrong, Lisa Knight, Michelle Jenkins, Portia Jackson, Rachel Logan, Tanya Lane, Jo Jenkins, Kieran Reynolds, Rosie Furner, Sandra Wolper
Intended Users:
Registered healthcare professionals authorized to operate under the PGD
Implementation Date:
1st April 2026
Review Date:
1st September 2028
Expiry Date:
31st March 2029
Version History:
Version 1 (April 2020), Version 1.1 (November 2020), Version 2.0 (April 2023), Version 2.1 (April 2024), Version 2.2 (April 2025), Version 2.3 (July 2025), Version 3.0 (October 2025)
Regulatory Reference:
Human Medicines Regulation 2012, Schedule 16 Part 4
Approval:
College of Sexual and Reproductive Healthcare (CoSRH), January 2026
Supporting Groups:
Reproductive Health PGDs Short Life Working Group (SLWG)
Contextual Scope:
Contraceptive medicine administration and patient safety guidelines